National Institute of Animal Biotechnology, Hyderabad can now conduct quality checks and consequent lot release of Covid-19 vaccines
This is the first of its kind vaccine for Covid 19 to get the go-ahead
The acquisition will provide it with a foothold in the US $ 48 billion global animal health market
A treatment to prevent extreme symptoms and cut hospitalisation
Asia-Pacific is projected to portray the fastest CAGR of 13.2 by 2030
The sales of vaccines have registered a growth of 41% in Q1 FY22, and the sale of health products have registered a growth of 94% in Q1 FY22.
The goal for the project is the identification and optimization of anti-viral compounds.
The company has already embarked upon significant expansion in Turkey
These vaccine doses will be manufactured and stockpiled by the company from August-December 2021
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Subscribe To Our Newsletter & Stay Updated
